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This study aimed to compare incidence, management and outcomes of women transfused
their blood volume or more within 24 hours during pregnancy or following childbirth.
Methods
Combined analysis of individual patient data, prospectively collected in six international pop-
ulation-based studies (France, United Kingdom, Italy, Australia, the Netherlands and Den-
mark). Massive transfusion in major obstetric haemorrhage was defined as transfusion of
eight or more units of red blood cells within 24 hours in a pregnant or postpartum woman.
Causes, management and outcomes of women with massive transfusion were compared
across countries using descriptive statistics.
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Findings
The incidence of massive transfusion was approximately 21 women per 100,000 maternities
for the United Kingdom, Australia and Italy; by contrast Denmark, the Netherlands and
France had incidences of 82, 66 and 69 per 100,000 maternities, respectively. There was
large variation in obstetric and haematological management across countries. Fibrinogen
products were used in 86% of women in Australia, while the Netherlands and Italy reported
lower use at 35–37% of women. Tranexamic acid was used in 75% of women in the Nether-
lands, but in less than half of women in the UK, Australia and Italy. In all countries, women
received large quantities of colloid/crystalloid fluids during resuscitation (>3�5 litres). There
was large variation in the use of compression sutures, embolisation and hysterectomy
across countries. There was no difference in maternal mortality; however, variable propor-
tions of women had cardiac arrests, renal failure and thrombotic events from 0–16%.
Interpretation
There was considerable variation in the incidence of massive transfusion associated with
major obstetric haemorrhage across six high-income countries. There were also large dis-
parities in both transfusion and obstetric management between these countries. There is a
requirement for detailed evaluation of evidence underlying current guidance. Furthermore,
cross-country comparison may empower countries to reference their clinical care against
that of other countries.
Introduction
The most common form of major obstetric haemorrhage (MOH), postpartum haemorrhage
(PPH) remains a major cause of maternal mortality and morbidity. PPH occurs in 3–7% of
deliveries in high-income settings [1]. In France, Italy and the United States, haemorrhage is
the leading cause of maternal mortality responsible for 11%, 15% and 14% of maternal deaths,
respectively [2–4] and haemorrhage related mortality in the United Kingdom (UK) nearly
doubled during the period 2010–12 to 2013–15 [5]. In addition, major obstetric haemorrhage
(MOH) is a common reason for admission to intensive care [6–9].
Management of MOH, often defined pragmatically as transfusion of a total body blood vol-
ume (8–10 units of red blood cells) or more within 24 hours of delivery [10–12] and also
referred to as massive transfusion, focusses on transfusion and fluid resuscitation, alongside
planning for definitive obstetric and surgical interventions [13]. The literature in major haem-
orrhage caused by trauma has emphasised the importance of damage control resuscitation,
including timely transfusion support, early use of coagulation factors and minimising use of
crystalloids, which have all contributed to improved clinical outcomes. However, it is unclear
how far these protocols should be applied in an obstetric setting [14].
Multiple guidelines to direct transfusion practice in MOH exist and these vary in terms of
when and what quantity of blood components should be given. The reasons for variation in
practice are unclear but are likely in part to reflect lack of high-quality data [15, 16]. A number
of national studies have reported the transfusion management of PPH [13, 17, 18], but there
has been little comparison reported at a national level to explore regional variations in practice.
As part of an initiative to inform the international research agenda, this exploratory study was
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planned to describe and compare the incidence, characteristics, aetiology, management and
outcomes of pregnant or postpartum women who have been transfused their total blood vol-




This international population-based study of massive transfusion in MOH, used secondary
analyses of data from six population-based studies from Australia, Denmark, France, Italy, the
Netherlands and the UK.
Overall description
Member countries of the International Network of Obstetric Survey Systems were invited to
provide national/sub national data on obstetric haemorrhage, and this included published and
non-published data. In each country, data were collected either nationally or from a number
of regions on a population basis using tailored data collection systems. A detailed explanation
of the methodology for each country is summarised in Table 1. In short, these population-
based studies collected data, using enhanced systems, from the medical records of the women
who met the case definition for each of the respective studies. Danish data were solely based
on information entered into the Danish Medical Birth Registry and the Danish Transfusion
Database, which included data from all hospitals in Denmark. Three of the included datasets
were national except for the Netherlands, France, and Italy. The TeMpOH-1 study in the Neth-
erlands collected data from 75% of national births. Italy collected data from six regions and
these represented 49% of births in Italy. The EPIMOMS study in France collected data from
six regions and these regions represented 18% of national births.
Case definition
Massive transfusion in major obstetric haemorrhage was defined as a receipt of eight or more
units of red blood cells within 24 hours in a pregnant or postpartum woman of at least 20
weeks of gestation.
Case notification and data collection
United Kingdom and Australia. Both countries used a national surveillance system to
identify cases of massive transfusion from consultant led obstetric units nationally in the
Table 1. Summary of data collection systems and data collected.
Country Name of system or dataset Type of system Date collected
Australia Australasian Maternity Outcomes Surveillance System
(AMOSS). [35]
National obstetric surveillance system. Collected data from
hospitals with more than 50 births per year.
One year (July 2014-June
2015)
Denmark Danish Medical Birth Registry and the Danish
Transfusion Database
Routinely collected national data on both birth and
transfusions.
Five years (2010–2015)
France Épidémiologic de la Morbidité Maternelle Sévère study
(EPIMOMS) [36]
Prospective Population-based study from all maternity
units in 6 regions.
One year (2012–2013)






Transfusion strategies in women during Major Obstetric
Haemorrhage study (TeMpOH-1) [37]




United Kingdom Obstetric Surveillance System (UKOSS)
[38]
Obstetric surveillance system which collected data
nationally from all consultant-led hospitals.
One year (June 2013- July
2014)
https://doi.org/10.1371/journal.pone.0244933.t001
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United Kingdom and from hospitals with over 50 births per year in Australia. Reporters were
asked to complete a data collection form using the medical records of the women. Data were
collected anonymously. The findings from the United Kingdom study have been published
previously [11, 12].
During the period 2014–2015, AMOSS identified women who had 5 or more units of RBCs
transfused within 24 hours at 20 weeks’ gestation or more. Between June 2013- July 2014,
women who had 8 or more units of RBCs transfused within 24 hours at 20 weeks’ gestation or
more were identified using the United Kingdom Obstetric Surveillance System.
France. This study included data from the EPIMOMS study that prospectively identified
cases of severe maternal morbidity from 6 regions in France: Alsace Champagne-Ardenne,
Lorraine, Auvergne, Rhone-Alpes, Ile-de-France and Normandy. Cases were identified for a
year between 2012–2013 from 113 intensive care units and 118 maternity units. Selected
maternal morbidities were identified by a local reporter in each hospital. Data about demo-
graphics, previous medical history, current pregnancy, causes, management and maternal and
perinatal outcomes were collected from the case notes of each women.
Major obstetric haemorrhage was one of the severe maternal morbidities included in the
EPIMOMS study. To be included as a MOH case, women had to be at least 22 weeks’ of gesta-
tion or more and had to meet one of the following criteria:�1500mls blood loss, blood
transfusion� 4 RBC, uterine artery embolisation, ligation or compressive uterine sutures or
have an emergency peripartum hysterectomy [19].
Italy. The Italian Obstetric Surveillance (ItOSS) system in Italy identified women who
had 4 or more units of RBCs transfused at 22 weeks’ gestation or greater. This prospective pop-
ulation-based study identified women during 2014–2016 from six regions in Italy, namely
Piedmont and Emilia-Romagna, Tuscany, Lazio, Campania and Sicily. The clinical reporter
from each facility identified and collected data on women with PPH, uterine rupture, abnor-
mally invasive placenta and peripartum hysterectomy. Clinical and demographic data were
collected from the woman’s medical records and entered into an online data collection form.
The completeness of the reported cases was verified through the Hospital Discharge Database.
The Netherlands. TeMpOH-1 was a national retrospective cohort study conducted
between January 2011 and January 2013 in the Netherlands. Women were identified using rec-
ords from blood transfusion services and birth registries of participating hospitals. Women
were included if they had received four units or more of RBCs or a multicomponent blood
transfusion as a result of obstetric haemorrhage. Data were collected from medical records and
included information about previous medical history, current pregnancy, causes of haemor-
rhage, haematological parameters, blood components, fluid resuscitation and surgical and
medical management.
Denmark. The Danish data were identified and collected using the Danish National Birth
Registry (DNBR) and the Danish Transfusion Database (DTD). During the period 2010–2015,
women who had a birth identified in the DNBR and had transfused 8 or more units of RBC
within 24 hours identified from DTD were included in study. The DNBR collects information
on all births in Denmark and this includes clinical and demographic data from each birth. The
DTD is a national database and contains information of the quantity and type of blood prod-
ucts transfused and the time of each transfusion.
Comparability of datasets
With reference to the literature, the clinical and demographic variables required to answer the
objectives were requested from the participating countries. Available desired variables were
provided by each country. Using data dictionaries from each country, each variable was
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mapped to assess the availability and comparability between datasets. If the components of a
particular variable were not comparable between the datasets, then a common definition for
that variable was created. If this was not possible the variable was excluded from the analysis.
A mapping exercise was completed to assess whether the coding matched; where coding dif-
fered, a harmonised coding was devised and applied. The included variables and issues with
comparability can be found in S1 Table.
Statistical analysis
Women’s characteristics, medical history, obstetric and transfusion management and maternal
outcomes were compared across countries. Normality was assessed using histograms. Nor-
mally distributed continuous variables were presented as means with standard deviations and
skewed continuous variables were presented as medians with interquartile ranges. The exact
binomial distribution was used to estimate confidence intervals for proportions. Statistical
hypothesis testing was carried out to test for statistical differences between countries and
respective characteristics, management and outcomes of women undergoing massive transfu-
sion. Descriptive analyses used the following tests where appropriate: Analysis of Variance
(ANOVA), Wilcoxon rank-sum test, Kruskal-Wallis test and chi square tests or the Fisher-
Freeman-Halton’s test. In order to reduce the risk of a type I error a p-value <0�01 was used to
indicate statistical significance. Missing data were included as a ‘missing’ category for categori-
cal variables. If a country did not collect the specified variable this was indicated by a dash in
tables. Complete case analysis was used for continuous variables.
Categorisation of aetiology of MOH. France had multiple causes of MOH coded, so a
primary cause was devised using a hierarchical approach. The primary cause was defined in
the following order: first those with abnormal placentation, second women with abruption,
third women with trauma and lastly those with atony.
Ethics approval and data sharing agreements
This study was a secondary data analysis of data collected from primary studies. All countries
had the required ethics approval for their primary studies and performed research following
the World Medical Association’s Declaration of Helsinki [20]. The UK, Italy, TeMpOH-1 (the
Netherlands), France and Australia had obtained ethics approval for the collection of anon-
ymised information without seeking the consent of the women from the London Multi-centre
Research Ethics Committee (MREC reference 04/MRE02/45), Italian National Institute of
Health (Prot. PRE-839/13, Rome 19/12/2013), Leiden University Medical Center, National
Data Protection Authority in France (CNIL, authorisation no. 912210, 14/3/2012), and from
the Human Research Ethics Committee, New South Wales, Australia and from Human
Research Ethics Committee for individual sites across Australia, respectively. Australia
obtained ethics approval for this secondary data analysis; this study was approved by the
Human Research Ethics Committee, New South Wales, Australia. The TeMpOH-1 study was
approved by the ethics committee of the Leiden University Medical Center and by the institu-
tional review board of each participating hospital; the TeMpOH-1 and ItOSS steering commit-
tees approved the study protocol and the data transfer agreement. The ethics committee at the
Leiden University Medical Center approved the study protocol. The French data collaborators
gained approval for this analysis from the EPIMOMS steering committee at INSERM, Paris.
Ethics committee approval for the secondary analysis of UK data was not required. The Danish
collaborators acquired permission from the Danish Data Protection Agency (J.nr: HGH-2016-
066), no permission was required from the Danish Ethics Committee according to Danish law.
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Results
Denmark reported the highest incidence of massive transfusion at 82 (95% CI: 73–92) women
per 100,000 deliveries; followed by France and the Netherlands with an incidence of 69 per
100,000 deliveries (95% CI: 58–82) and 66 per 100,000 deliveries (95% CI: 57–77), respectively.
The UK, Australia and Italy had a similar incidence of massive transfusion at approximately 21
women per 100,000 deliveries (Table 2). These variable rates are seen despite many similarities
in baseline characteristics of women presenting with PPH, including age and BMI.
Mean age of women with massive transfusion was 32 years (SD ±5�7), and the majority
were multiparous (57%). Amongst women with a previous pregnancy, there were differences
between countries in the proportion of women with previous caesarean section and previous
postpartum haemorrhage (previous caesarean section: highest in the UK (66%) and lowest in
Australia (39%)).
Amongst cases, there were differences in the proportions of women with multiple pregnancies
between countries (Denmark 24%, France 14% and UK 4%, respectively). In addition, the major-
ity of women were delivered by caesarean section in each country (range excluding the Nether-
lands: 59%-68%), while the Netherlands had the lowest proportion of caesarean deliveries at 42%.
The most common cause of MOH in all countries was atony, with a prevalence ranging
from 40% in the UK to 63% in the Netherlands (S2 Table). The second leading cause was
abnormal placentation with a prevalence ranging from 22% in Italy and the Netherlands to
32% in Australia. The least common cause was placental abruption with a proportion ranging
from 3% in the Netherlands and Italy to 9% in the UK.
Use of blood components varied across countries, Italy had a smaller median use of fresh
frozen plasma (FFP) and platelets compared to other countries (Table 3). France had the high-
est use of FFP with a median of 7 units (IQR: 5–9) compared with the other countries. The
inter country difference in use of FFP was statistically significant (P<0�01).
Different concentrated sources of fibrinogen were used, the UK and Australia mainly
administered cryoprecipitate while France, Italy and the Netherlands used fibrinogen concen-
trate. The highest proportion of women receiving a fibrinogen product was in Australia (86%),
while the Netherlands and Italy had the lowest use (35–37%) compared to the other countries
(64%-86%).
Between 13–16% of women received factor VIIa in Italy, France and the Netherlands while
the United Kingdom reported the lowest use at 8%, although this difference was not statisti-
cally significant. Use of tranexamic acid (TXA) also varied between countries, the Netherlands
used TXA in 75% of women with massive transfusion while it was used in less than a half of
women in the UK, Australia and Italy, and these differences were statistically significant. Large
amounts of colloid and crystalloid fluids were transfused; the median fluid transfusion was
between 3.5 and 4.5 litres in Italy, the Netherlands and the UK.
The use of surgical techniques and interventional radiology also varied between countries
(Table 4). An intrauterine balloon was used in at least half of all women with massive transfusion
except in France where a balloon was only used in a third of women. Use of arterial embolisation
and major vessel ligation was more common in France and the Netherlands (71% and 52% of
women, respectively) compared to the UK and Italy (16% and 4% of women, respectively).
Uterine compression sutures were more commonly used in Australia, France and the UK
(36%-24%) compared to the remaining countries (13–14%). In Italy, 74% of women with a
massive transfusion had a hysterectomy, compared with less than half of women in the United
Kingdom, France, and a third of women in the Netherlands.
Overall there were fourteen maternal deaths which gave a case fatality of 1.5% (95% CI: 0.8–
2.6) (Table 5). Nevertheless, maternal mortality was rare across all countries. Fifteen women had
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Table 2. Sociodemographic, previous medical history and current pregnancy information in women undergoing massive transfusion for major obstetric
haemorrhage.
UK n = 162 Australia
n = 61








National denominator 787,105 302,666 458,995 270,101 182,309 349,998












Age Mean (Std) 33 (5�9) 33 (5�3) 35 (6�1) 32 (5�3) 33 (5�9) 32 (5�4) <0�001














Parity Nulliparous 60 (37�3) 20 (32�8) 48 (48�5) 84 (46�9) 56 (44�8) 128 (44�8) 0�185
Multiparous 101 (62�7) 41 (67�2) 51 (51�5) 95 (53�1) 69 (55�2) 158 (55�2)
Missing 1 0 0 0 1 2
Previous caesarean section None 35 (34�3) 25 (61) 23 (46�9) 51 (53�7) 38 (55�9) 77 (48�1) 0�020
Yes 67 (65�7) 16 (39) 26 (53�1) 44 (46�3) 30 (44�1) 83 (51�9)
Nulliparous 60 20 48 84 56 128
Missing 0 0 2 0 2 0
Number of previous caesarean section 0 35 (34�3) 25 (61) 23 (46�9) - - 38 (55�9) - - 0.036
1 38 (37�3) 10 (24�4) 16 (32�7) - - 21 (30�9) - -
2+ 29 (28�4) 6 (14�6) 10 (20�4) - - 9 (13�2) - -
Nulliparous 60 20 48 - - 56 - -
Missing 0 0 2 2
Previous postpartum haemorrhage None 78 (76�5) 29 (85�3) 41 (91�1) 86 (91�5) 64 (92�8) - - 0�007
Yes 24 (23�5) 5 (14�7) 4 (8�9) 8 (8�5) 5 (7�2) - -
Nulliparous 60 20 48 84 56 - -
Missing 0 7 6 1 1 - -
Current pregnancy
Hypertension prior to pregnancy or current
problem
None 161 (99�4) 59 (96�7) 94 (94�9) 153 (85�5) 124 (99�2) - - <0�001
Yes 1 (0�6) 2 (3�3) 5 (5�1) 26 (14�5) 1 (0�8) - -
Missing 0 0 0 0 1 - -
Infection in current pregnancy No 161 (99�4) 56 (94�9) 99 (100) 179 (100) 117 (97�5) - - 0�006�
Yes 1 (0�6) 3 (5�1) 0 (0) 0 (0) 3 (2�5) - -
Missing 0 2 0 0 6 - -
Inherited bleeding disorders No 160 (98�8) 55 (98�2) - - - - 121 (96�8) - - 0�602�
Yes 2 (1�2) 1 (1�8) - - - - 4 (3�2) - -
Missing 0 5 - - - - 1 - -
Multiple pregnancy No 155 (95�7) 58 (95�1) 92 (92�9) 167 (93�8) 108 (85�7) 219 (76) <0�001
Yes 7 (4�3) 3 (4�9) 7 (7�1) 11 (6�2) 18 (14�3) 69 (24)
Missing 0 0 0 1 0 0
Induced None 103 (65�2) 20 (54�1) 56 (73�7) 117 (65�4) 52 (41�6) - - <0�001
Yes 55 (34�8) 17 (45�9) 20 (26�3) 62 (34�6) 73 (58�4) - -
Missing 4 24 23 0 1 - -
Delivery type Vaginal delivery 50 (31�6) 25 (41) 37 (37�4) 104 (58�4) 47 (37�6) 92 (31�9) <0�001
Caesarean
delivery
108 (68�4) 36 (59) 62 (62�6) 74 (41�6) 78 (62�4) 196 (68�1)
N/A Pregnancy
loss
4 0 0 1 1 0
�Used Fisher’s exact test.
Missing data were not included in the percentage. A dash indicated that the country did not collect data on that specific variable.
https://doi.org/10.1371/journal.pone.0244933.t002
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Table 3. Haematological management by country.
Blood products UK n = 162 Australia
n = 61







Number of RBC units Median
(IQR)





Received Fresh frozen plasma n (%) 162 (100) 59 (96�7) 84 (84�8) 179 (100) 126 (100) 247 (85�8) <0�001
Fresh frozen plasma Median
(IQR)
6 (4–8) 6 (4–8) 4 (2–8) 6 (4–8) 7 (5–9) 6 (4–8) <0�001
Received Platelets n (%) 126 (77�8) 51 (83�6) 40 (40�4) 179 (100) 126 (100) 205 (71�2) <0�001
Platelets Median
(IQR)
1 (1–2) 1 (1–2) 0 (0–2) 2 (1–3) 1 (1–3) 2 (0–3) <0�001
Source of concentrated fibrinogen
administered
No 58 (35�8) 8 (13�6) 62 (62�6) 116 (64�8) 27 (22�3) - - <0�001
Yes 104 (64�2) 51 (86�4) 37 (37�4) 63 (35�2) 94 (77�7) - -
Missing 0 2 0 0 5 - -
Fibrinogen concentrate used No 152 (93�8) 54 (100) 62 (62�6) 116 (64�8) 27 (22�3) - - <0�001
Yes 10 (6�2) 0 (0) 37 (37�4) 63 (35�2) 94 (77�7) - -
Missing 0 7 0 0 5 - -
Cryoprecipitate used No 55 (35�5) 8 (13�6) - - - - - - - - 0�002
Yes 100 (64�5) 51 (86�4) - - - - - - - -
Missing 7 2 - - - - - - - -
Number of units of cryoprecipitate Median
(IQR)
2 (0–2) 1 (1–2) - - - - - - - - 0.07
Use of cell salvage No 115 (74�2) 46 (85�2) - - - - - - - - 0�098
Yes 40 (25�8) 8 (14�8) - - - - - - - -
Missing 7 7 - - - - - - - -






- - - - - - - - 0.95
Recombinant Factor VIIa No 149 (92) 48 (90�6) 86 (86�9) 151 (84�4) 103 (85�1) - - 0�224
Yes 13 (8) 5 (9�4) 13 (13�1) 28 (15�6) 18 (14�9) - -
Missing 0 8 0 0 5 - -
Tranexamic acid No 87 (53�7) 41 (74�5) 57 (57�6) 45 (25�1) 47 (39�2) - - <0�001
Yes 75 (46�3) 14 (25�5) 42 (42�4) 134 (74�9) 73 (60�8) - -
Missing 0 6 0 0 6 - -
Any fluid used during resuscitation�� No 4 (2�5) 42 (77�8) 0 (0) 0 (0) 0 (0) - - <0�001�
Yes 157 (97�5) 12 (22�2) 55 (100) 167 (100) 108 (100) - -
Missing 1 7 44 12 18 - -







Colloid Yes 139 (88�5) - - 49 (98) 160 (96�4) 87 (82�9) - - <0�001�
Missing 5 - - 49 13 21 - -








- - - - <0�001
Crystalloid Yes 152 (95) - - 49 (100) 137 (100) 103 (95�4) - - 0�013�
Missing 2 - - 50 42 18 - -








- - - - 0�442
�Used Fisher’s exact test.
��Australia only recorded use of 5 and 25% albumin administration.
Missing data were not included in the percentage. A dash indicated that the country did not collect data on that specific variable.
https://doi.org/10.1371/journal.pone.0244933.t003
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a thrombotic event; women in France had about double the proportion of these events compared
to the UK and Australia (6% vs. ~3%, respectively). In addition, France had a higher proportion
of renal failure compared to other countries (16% vs. ~1–2%, respectively). Furthermore, France
had a slightly higher proportion of cardiac arrests compared to other countries (8% vs. ~1–5%).
Discussion
This population-based study has shown a five-fold variation in the incidence of massive trans-
fusion across six high-income countries with similarly well-developed healthcare systems and
medical resources. Despite the same primary evidence being available to clinicians and
Table 4. Obstetric management by country.
UK n = 162 Australia
n = 61
Italy n = 99 the Netherlands
n = 179




Oxytocin No 6 (3�7) 7 (11�7) 26 (26�3) 65 (36�3) 47 (39�5) - - <0�001
Yes 156 (96�3) 53 (88�3) 73 (73�7) 114 (63�7) 72 (60�5) - -
Missing 1 0 7 - -
Ergometrine No 69 (42�6) 32 (56�1) - - 160 (89�4) - - - - <0�001
Yes 93 (57�4) 25 (43�9) - - 19 (10�6) - - - -
Missing 4 - -
Prostaglandin No 64 (39�5) 30 (52�6) 49 (49�5) 30 (16�8) 16 (13�6) - - <0�001
Yes 98 (60�5) 27 (47�4) 50 (50�5) 149 (83�2) 102 (86�4) - -
Missing 4 0 8 - -
Misoprostol No 73 (45�1) 29 (51�8) - - 117 (65�4) 118 (99�2) - - <0�001
Yes 89 (54�9) 27 (48�2) - - 62 (34�6) 1 (0�8) - -
Missing 5 7 - -
Any uterotonic treatment No 5 (3�1) 3 (5) 21 (21�2) 13 (7�3) 9 (7�5) - - <0�001
Yes 157 (96�9) 57 (95) 78 (78�8) 166 (92�7) 111 (92�5) - -
1 6 - -
Surgical management
Intrauterine balloons No 68 (42) 26 (44�8) 45 (45�5) 77 (43) 88 (72�1) 246 (85�4) <0�001
Yes 94 (58) 32 (55�2) 54 (54�5) 102 (57) 34 (27�9) 42 (14�6)
Missing 0 3 0 0 4
Intra-abdominal packing� No 147 (90�7) 47 (83�9) - - - - 109 (90�1) - - 0�344
Yes 15 (9�3) 9 (16�1) - - - - 12 (9�9) - -
Missing 5 - - - - 5 - -
Embolisaton or ligation No 136 (84) 41 (67�2) 95 (96) 86 (48) 36 (29�5) 286 (99�3) <0�001
Yes 26 (16) 20 (32�8) 4 (4) 93 (52) 86 (70�5) 2 (0�7)
Missing 4
Compressive sutures No 123 (75�9) 38 (64�4) 86 (86�9) 154 (86) 90 (73�8) 247 (85�8) <0�001
Yes 39 (24�1) 21 (35�6) 13 (13�1) 25 (14) 32 (26�2) 41 (14�2)
Missing 0 2 0 0 4
Hysterectomy No 87 (53�7) 29 (47�5) 26 (26�3) 126 (70�4) 66 (54�5) 223 (77�4) <0�001
Yes 75 (46�3) 32 (52�5) 73 (73�7) 53 (29�6) 55 (45�5) 65 (22�6)
Missing 0 0 0 0 5 0
� Italian and Danish data include intrauterine packing.
The Netherlands: intra-abdominal packing was after hysterectomy and was not included. Missing data were not included in the percentage. A dash indicated that the
country did not collect data on that specific variable.
https://doi.org/10.1371/journal.pone.0244933.t004
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guideline writers, in each country different obstetric and haematological management is pro-
vided for the management of women undergoing transfusion in major obstetric haemorrhage.
Although there were no differences in maternal mortality between countries, these numbers
are low, and there was evidence of highly variable rates of cardiac arrest, thrombotic events
and renal failure. The greatest variation in resuscitation was seen for use of fibrinogen prod-
ucts, tranexamic acid and recombinant factor VIIa. Again, there was striking variation in
obstetric management including the use of intrauterine balloons, embolisation and hysterec-
tomy between countries.
The variation in incidence between countries is likely to be multifactorial. Variations in
obstetric management may be a relevant factor, for example, differential thresholds for peri-
partum hysterectomy may be a potential determinant of the inter country differences. More
timely recognition, and control of bleeding may prevent worsening to more severe bleeds (�8
units), and therefore factors that delay presentation and definitive management need to be
explored between countries. National support for robust MOH protocols through appropriate
fluid and haematological management may also control the bleeding at earlier stages. Other
factors include case-mix and variation in risk factors such as the caesarean section rate, and
rate of multiple pregnancies. However, the data collected in each country did not include
information about the general obstetric population, so there may be other differences in back-
ground risks for PPH between countries that have not been captured. Alternatively, the varia-
tion in incidence of massive transfusion may be a reflection of differential transfusion policies.
Table 5. Maternal outcomes by country.
UK n = 162 Australia n = 61 Italy n = 99 the Netherlands
n = 179
France n = 126 Denmark n = 288 P-value
Maternal outcome
Maternal death No 160 (98�8) 61 (100) 96 (97) 175 (97�8) 123 (97�6) 286 (99�3) 0�37�
Yes 2 (1�2) 0 (0) 3 (3) 4 (2�2) 3 (2�4) 2 (0�7)
Cardiac arrest No 154 (95�1) 57 (96�6) 94 (94�9) - - 116 (92�1) 285 (99) 0�005�
Yes 8 (4�9) 2 (3�4) 5 (5�1) - - 10 (7�9) 3 (1)
Missing 0 2 0 0 0
Renal failure
No 160 (98�8) 58 (98�3) 97 (98) - - 106 (84�1) 284 (98�6) <0�001�
Yes 2 (1�2) 1 (1�7) 2 (2) - - 20 (15�9) 4 (1�4)
Missing 2 0 0
Infection
No 157 (96�9) 56 (96�6) 97 (98) - - 118 (93�7) - - 0�399�
Yes 5 (3�1) 2 (3�4) 2 (2) - - 8 (6�3) - -
Missing 0 3 0 0
Thrombotic event No 158 (97�5) 57 (96�6) 99 (100) - - 118 (93�7) 287 (99�7) 0�001�
Yes 4 (2�5) 2 (3�4) 0 (0) - - 8 (6�3) 1 (0�3)
Missing 0 2 0 - - 0 0
ITU admission No 30 (18�5) 2 (3�3) 15 (15�3) 32 (17�9) 44 (34�9) - - <0�001
Yes 132 (81�5) 59 (96�7) 83 (84�7) 147 (82�1) 82 (65�1) - -
�Used Fisher’s exact test.
Maternal outcomes: Cardiac arrest: UK included—cardiac arrest, cardiac infection and cardioversion and inotropic support; Italy, Australia and France: cardiac arrest.
Infection: UK: chest infection, septicaemia, septic shock, sepsis, enterococcus infection, necrotising fasciitis, C. difficile, abscess, suspected tuberculosis or meningitis,
wound infection and wound dehiscence. Australia: sepsis. Italy and France: septicaemia. Thrombotic: pulmonary embolism or deep venous thrombosis.
Missing data were not included in the percentage. A dash indicated that the country did not collect data on that specific variable. ITU: Intensive therapy unit.
https://doi.org/10.1371/journal.pone.0244933.t005
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Guidelines for the haematological and fluid resuscitation management of haemorrhage
vary by country and medical specialty [16]. Consequently, it is not surprising that clinical prac-
tice and use of blood components differed by country.
Clinicians in the UK and Australia mainly used cryoprecipitate as a source of concentrated
fibrinogen while in Italy, France and the Netherlands clinicians only used fibrinogen concen-
trate. There is a paucity of evidence regarding the efficacy of, optimal source and dose of
fibrinogen. The FIB-PPH trial compared the use of fibrinogen concentrate to placebo in the
initial treatment of PPH, but the intervention did not reduce the primary outcome of postpar-
tum bleeding [21]; the study explored the efficacy of fibrinogen concentrate among a wide
range of cases including non-severe PPH. The FIBRES trial conducted in cardiac surgery
showed that fibrinogen was noninferior to cryoprecipitate [22]. While this study focused on
sources of concentrated fibrinogen, FFP is also a source of fibrinogen; however, FFP has a
much lower concentration of fibrinogen than fibrinogen concentrate or cryoprecipitate. Con-
sequently, FFP is not recommended as a primary agent for fibrinogen concentration [23, 24].
At the time of the data collection for this study there was a lack of high-quality evidence
about the use of TXA in the treatment of obstetric haemorrhage, and there was variation in
use. Trials were either too small to detect a statistically significant difference in the primary
outcome [25] or did not have the power to examine safety issues of the drug [26]. The findings
of the WOMAN trial have now been published and it would be of interest to understand how
this trial has changed TXA use [27].
In the majority of countries, current guidelines and expert reviews recommend that recom-
binant factor VIIa should not be given in obstetric haemorrhage [16, 28, 29]. A Cochrane
review reported no evidence to support the efficacy of recombinant factor VIIa across a range
of clinical settings as prophylaxis or therapeutically; but with evidence to indicate an increased
risk of thromboembolic events [30]. French guidelines allow for the use of recombinant factor
VIIa as a “compassionate treatment” to avoid a hysterectomy in nulliparous women or for life-
threatening situations [31]. Overall, despite lack of evidence of benefit alongside risks and high
costs, approximately 12% of women across all 6 countries received the pro-haemostatic agent
in this international study.
Previous research has shown that obstetric management of PPH varies internationally [32–
34]. The findings from this study are consistent with this, as embolisation use was higher in
France and the Netherlands in comparison to the UK. This most likely reflects the availability
of the infrastructure required to provide an embolisation service as well as perceived efficacy.
Intrauterine balloon tamponade is the most common second stage management of MOH and
its lower use in France most likely reflects higher use of embolisation.
This study also showed a significant disparity in the use of hysterectomy where three-quar-
ters of women had a hysterectomy in Italy while only a third of women did so in the Nether-
lands and less than a fifth in Denmark. Consistent with previous research, a similar proportion
of women in the UK and France had a hysterectomy [32]. With no difference in maternal mor-
tality between countries, this suggests that the future fertility of some of these women could
have been saved.
There was no difference in maternal mortality between countries. However, this study may
not have been adequately powered to test for differences in this rare event. A higher number of
women with massive transfusion in France had renal failure, cardiac arrests and thrombotic
events. The reasons are unclear but higher rates of pro-haemostatic agents were reported.
However, the EPIMOMS study included specific questions on these outcomes within their
data collection form, which may have resulted in better ascertainment than the UK, Italy and
Australia.
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This study was unique in its ability to compare all women between populations, based on
national or regional studies with women who had been transfused at least eight of more units
of red blood cells. This study used similar methods to an individual patient data meta-analysis.
This methodology allowed the harmonisation of definitions and creation of comparable data-
sets, which in turn allowed robust comparisons between nations. All countries except for Den-
mark had tailored data collection forms, which collected detailed information about each
woman, and enabled this unique comparison.
This analysis should be interpreted in the context of its limitations. Each national study col-
lected slightly different items. To reduce errors due to misclassification all countries had their
cases cross-checked against hospital records, other than Denmark, which was solely based on
ICD-10-CM codes.
This analysis was also susceptible to survival bias, as those women who died or had a hyster-
ectomy before they received 8 units of RBC would not have been included in the study popula-
tion. To overcome this limitation, future epidemiological studies should use a composite of
inclusion criteria to prevent survival bias. This composite should include women who died
from a haemorrhage, women who have a hysterectomy or surgical management due to uncon-
trolled bleeding, women who meet a certain number of RBC units transfused or where a major
obstetric haemorrhage protocol has been activated. Furthermore, women with haemorrhage
before 20 weeks of gestation were not included in the case definition, thus most women with a
major haemorrhage as a result of an ectopic pregnancy would have been excluded. In addition,
the surveillance systems in UK, Australia and Italy may not have identified women with sec-
ondary PPH who were not readmitted to an obstetric unit, whilst hospital databases and blood
banks in Denmark, the Netherlands and France were interrogated to ensure obstetric related
haemorrhages after pregnancy were included. It is unlikely, however, that differences in regis-
tration are responsible for the marked variation seen in incidence.
Conclusion
There was a considerable variation in the incidence of massive transfusion associated with
major obstetric haemorrhage between countries. This may be the result of disparities in the
timely management of less severe bleeds between countries or differences in transfusion poli-
cies; however, more research is required to ascertain reasons for these differences. Obstetric
management and the use of blood products and haemostatic agents varied substantially. How-
ever, despite these variations in management, the rate of maternal mortality was similar.
Therefore, there is need for a detailed evaluation of the evidence underlying current guidance,
including the use of fibrinogen concentrate and other pro-thrombotic agents.
Summary
In the absence of high-level evidence, each country has a preferred treatment regimen, which
may lead to the use of unnecessary costly haematological products, exposure of women to
potential adverse effects and radical management such as hysterectomy. With wide variation
in obstetric practice, including hysterectomy and embolisation, significant improvement in
the evidence base is required particularly if a woman’s future fertility could be otherwise pre-
served. In extreme scenarios there is a delicate balance between saving a woman’s life and her
fertility, however, with a 40% difference in use of hysterectomy between Italy and the Nether-
lands and no difference in maternal mortality, there must be an examination and comparison
of the clinical pathway to ascertain if hysterectomy was necessary.
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cologie Obstétrique Fertilité & Sénologie 2017;45(12, Supplement):S8–S21. https://doi.org/10.1016/j.
gofs.2017.10.025.
3. Brantley M, Callaghan W, Cornell A, David N, Foster S, Goodman D, et al. Report from nine maternal
mortality review committees. Atlanta: CDC Division of Reproductive Health, 2018.
4. Donati S, Maraschini A, Lega I, D’Aloja P, Buoncristiano M, Manno V, et al. Maternal mortality in Italy:
Results and perspectives of record-linkage analysis. Acta Obstetricia et Gynecologica Scandinavica.
2018; 97(11):1317–24. https://doi.org/10.1111/aogs.13415 PMID: 29956300
5. Knight M, Nair M, Tuffnell D, Shakespeare J, Kenyon S, Kurinczuk J, et al. Saving Lives, Improving
Mothers’ Care—Lessons learned to inform maternity care from the UK and Ireland Confidential Enquir-
ies into Maternal Deaths and Morbidity 2013–15. Oxford: National Perinatal Epidemiology Unit, Univer-
sity of Oxford. 2017.
6. Sullivan EA, Hall B, King JF. Maternal deaths in Australia 2003–2005. Sidney: AIHW National Perinatal
Epidemiology Research Unit, 2007.
7. Wanderer JP, Leffert LR, Mhyre JM, Kuklina EV, Callaghan WM, Bateman BT. Epidemiology of Obstet-
ric-Related Intensive Care Unit Admissions in Maryland: 1999–2008. Critical Care Medicine. 2013; 41
(8):1844. https://doi.org/10.1097/CCM.0b013e31828a3e24 PMID: 23648568
8. Barry Y, Deneux-Tharaux C, Saucedo M, Goulet V, Guseva-Canu I, Regnault N, et al. Maternal admis-
sions to intensive care units in France: Trends in rates, causes and severity from 2010 to 2014. Anaes-
thesia Critical Care & Pain Medicine. 2019; 38(4):363–9. https://doi.org/10.1016/j.accpm.2018.12.007
PMID: 30583117
9. Zhao Z, Han S, Yao G, Li S, Li W, Zhao Y, et al. Pregnancy-Related ICU Admissions From 2008 to
2016 in China: A First Multicenter Report. Critical care medicine. 2018; 46(10):e1002. https://doi.org/10.
1097/CCM.0000000000003355 PMID: 30059363
10. McKinnon Edwards H. Aetiology and treatment of severe postpartum haemorrhage. Copenhagen: Uni-
versity of Copenhagen; 2017.
11. Green L, Knight M, Seeney F, Hopkinson C, Collins PW, Collis RE, et al. The haematological features
and transfusion management of women who required massive transfusion for major obstetric haemor-
rhage in the UK: a population based study. Br J Haematol. 2016; 172(4):616–24. https://doi.org/10.
1111/bjh.13864 PMID: 26683982
12. Green L, Knight M, Seeney FM, Hopkinson C, Collins PW, Collis RE, et al. The epidemiology and out-
comes of women with postpartum haemorrhage requiring massive transfusion with eight or more units
of red cells: a national cross-sectional study. BJOG: An International Journal of Obstetrics & Gynaecol-
ogy. 2016; 123(13):2164–70. https://doi.org/10.1111/1471-0528.13831 PMID: 26694742
13. Ramler PI, van den Akker T, Henriquez DD, Zwart JJ, van Roosmalen J. Incidence, management and
outcome of women requiring massive transfusion after childbirth in the Netherlands: secondary analysis
of a nationwide cohort study between 2004 and 2006. BMC pregnancy and childbirth. 2017; 17(1):197.
https://doi.org/10.1186/s12884-017-1384-7 PMID: 28629440
14. Henriquez DD, Bloemenkamp KW, van der Bom JG. Management of postpartum hemorrhage: how to
improve maternal outcomes? Journal of Thrombosis and Haemostasis. 2018; 16(8):1523–34. https://
doi.org/10.1111/jth.14200 PMID: 29883040
15. Dahlke JD, Mendez-Figueroa H, Maggio L, Hauspurg AK, Sperling JD, Chauhan SP, et al. Prevention
and management of postpartum hemorrhage: a comparison of 4 national guidelines. American Journal
of Obstetrics & Gynecology. 2015; 213(1):76.e1–.e10. https://doi.org/10.1016/j.ajog.2015.02.023
PMID: 25731692
16. Shaylor R, Weiniger CF, Austin N, Tzabazis A, Shander A, Goodnough LT, et al. National and Interna-
tional Guidelines for Patient Blood Management in Obstetrics: A Qualitative Review. Anesthesia & Anal-
gesia. 2017; 124(1):216–32. https://doi.org/10.1213/ANE.0000000000001473 PMID: 27557476
17. Patterson JA, Roberts CL, Bowen JR, Irving DO, Isbister JP, Morris JM, et al. Blood transfusion during
pregnancy, birth, and the postnatal period. Obstetrics & Gynecology. 2014; 123(1):126–33.
18. Deleu F, Deneux-Tharaux C, Chiesa-Dubruille C, Seco A, Bonnet M, group Es. A population-based
analysis of French transfusion practices for women experiencing severe postpartum hemorrhage. Inter-
national Journal of Obstetric Anesthesia. 2019; 42:11–19. https://doi.org/10.1016/j.ijoa.2019.07.006
PMID: 31402309
19. Deneux-Tharaux C, Bouvier-Colle M-H. 585: Severe acute maternal morbidity in France: the epimoms
population-based study. American Journal of Obstetrics & Gynecology. 2017; 216(1):S345–S6. https://
doi.org/10.1016/j.ajog.2016.11.319
20. Association WM. World Medical Association Declaration of Helsinki. Ethical principles for medical
research involving human subjects. Bulletin of the World Health Organization. 2001; 79(4):373. PMID:
11357217
PLOS ONE Massive blood transfusion during pregnancy or after childbirth
PLOS ONE | https://doi.org/10.1371/journal.pone.0244933 January 22, 2021 14 / 15
21. Wikkelsø A, Edwards H, Afshari A, Stensballe J, Langhoff-Roos J, Albrechtsen C, et al. Pre-emptive
treatment with fibrinogen concentrate for postpartum haemorrhage: randomized controlled trial. British
Journal of Anaesthesia. 2015; 114(4):623–33. https://doi.org/10.1093/bja/aeu444 PMID: 25586727
22. Callum J, Farkouh ME, Scales DC, Heddle NM, Crowther M, Rao V, et al. Effect of fibrinogen concen-
trate vs cryoprecipitate on blood component transfusion after cardiac surgery: the FIBRES randomized
clinical trial. JAMA. 2019; 322(20):1966–76. https://doi.org/10.1001/jama.2019.17312 PMID: 31634905
23. Nascimento B, Goodnough L, Levy J. Cryoprecipitate therapy. British Journal of Anaesthesia. 2014;
113(6):922–34. https://doi.org/10.1093/bja/aeu158 PMID: 24972790
24. Levy JH, Szlam F, Tanaka KA, Sniecienski RM. Fibrinogen and hemostasis: a primary hemostatic tar-
get for the management of acquired bleeding. Anesthesia & Analgesia. 2012; 114(2):261–74. https://
doi.org/10.1213/ANE.0b013e31822e1853 PMID: 21965371
25. Xu J, Gao W, Ju Y. Tranexamic acid for the prevention of postpartum hemorrhage after cesarean sec-
tion: a double-blind randomization trial. Archives of Gynecology and Obstetrics. 2013; 287(3):463–8.
https://doi.org/10.1007/s00404-012-2593-y PMID: 23064441
26. Ducloy-Bouthors A-S, Jude B, Duhamel A, Broisin F, Huissoud C, Keita-Meyer H, et al. High-dose tra-
nexamic acid reduces blood loss in postpartum haemorrhage. Critical Care. 2011; 15(2):R117. https://
doi.org/10.1186/cc10143 PMID: 21496253
27. WOMAN Trial Collaborators. Effect of early tranexamic acid administration on mortality, hysterectomy,
and other morbidities in women with post-partum haemorrhage (WOMAN): an international, rando-
mised, double-blind, placebo-controlled trial. The Lancet. 2017; 389(10084):2105. https://doi.org/10.
1016/S0140-6736(17)30638-4
28. Sentilhes L, Vayssière C, Deneux-Tharaux C, Aya AG, Bayoumeu F, Bonnet M-P, et al. Postpartum
hemorrhage: guidelines for clinical practice from the French College of Gynaecologists and Obstetri-
cians (CNGOF): in collaboration with the French Society of Anesthesiology and Intensive Care (SFAR).
European Journal of Obstetrics & Gynecology and Reproductive Biology. 2016; 198:12–21. http://dx.
doi.org/10.1016/j.ejogrb.2015.12.012.
29. Hunt BJ, Allard S, Keeling D, Norfolk D, Stanworth SJ, Pendry K, et al. A practical guideline for the hae-
matological management of major haemorrhage. British Journal of Haematology. 2015; 170(6):788–
803. https://doi.org/10.1111/bjh.13580 PMID: 26147359
30. Simpson E, Lin Y, Stanworth S, Birchall J, Doree C, Hyde C. Recombinant factor VIIa for the prevention
and treatment of bleeding in patients without haemophilia. Cochrane Database of Systematic Reviews.
2012;(3). https://doi.org/10.1002/14651858.CD005011.pub4 PMID: 22419303
31. Goffinet F, Mercier F, Teyssier V, Pierre F, Dreyfus M, Mignon A, et al. Postpartum haemorrhage: rec-
ommendations for clinical practice by the CNGOF (December 2004). Gynecologie, Obstetrique & Ferti-
lite. 2005; 33(4):268–74. https://doi.org/10.1016/j.gyobfe.2005.03.016 PMID: 15894217
32. Kayem G, Dupont C, Bouvier-Colle M, Rudigoz R, Deneux-Tharaux C. Invasive therapies for primary
postpartum haemorrhage: a population-based study in France. BJOG: An International Journal of
Obstetrics & Gynaecology. 2016; 123(4):598–605. https://doi.org/10.1111/1471-0528.13477
33. Zwart JJ, Dijk PD, van Roosmalen J. Peripartum hysterectomy and arterial embolization for major
obstetric hemorrhage: a 2-year nationwide cohort study in the Netherlands. American Journal of Obstet-
rics & Gynecology. 2010; 202(2):150.e1–7. https://doi.org/10.1016/j.ajog.2009.09.003 PMID:
19922900
34. Bonnet M-P, Basso O, Bouvier-Colle M-H, Dupont C, Rudigoz R-C, Fuhrer R, et al. Postpartum haem-
orrhage in Canada and France: a population-based comparison. PloS one. 2013; 8(6):e66882. https://
doi.org/10.1371/journal.pone.0066882 PMID: 23826165
35. Halliday LE, Peek MJ, Ellwood DA, Homer C, Knight M, McLintock C, et al. The Australasian Maternity
Outcomes Surveillance System: An evaluation of stakeholder engagement, usefulness, simplicity,
acceptability, data quality and stability. Australian and New Zealand Journal of Obstetrics and Gynae-
cology. 2012;53. https://doi.org/10.1111/ajo.12020 PMID: 23216366
36. Korb D, Goffinet F, Seco A, Chevret S, Deneux-Tharaux C. Risk of severe maternal morbidity associ-
ated with cesarean delivery and the role of maternal age: a population-based propensity score analysis.
CMAJ. 2019; 191(13):E352–E60. https://doi.org/10.1503/cmaj.181067 PMID: 30936165
37. Henriquez DD, Bloemenkamp KW, Loeff RM, Zwart JJ, van Roosmalen JJ, Zwaginga JJ, et al. Fluid
resuscitation during persistent postpartum haemorrhage and maternal outcome: A nationwide cohort
study. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2019; 235:49–56.
https://doi.org/10.1016/j.ejogrb.2019.01.027 PMID: 30784827
38. Knight M, Kurinczuk JJ, Tuffnell D, Brocklehurst P. The UK Obstetric Surveillance System for rare disor-
ders of pregnancy. BJOG: An International Journal of Obstetrics & Gynaecology. 2005; 112(3):263–5.
https://doi.org/10.1111/j.1471-0528.2005.00609.x PMID: 15713136
PLOS ONE Massive blood transfusion during pregnancy or after childbirth
PLOS ONE | https://doi.org/10.1371/journal.pone.0244933 January 22, 2021 15 / 15
